Generic Products (August 2019)

Pharmacy Times, August 2019 Back to School, Volume 85, Issue 8

New generic products for August 2019.

OSELTAMIVIR PHOSPHATE CAPSULESMARKETED BY: Alembic Pharmaceuticals

COMPARE TO: Tamiflu

Alembic Pharmaceuticals has received FDA approval for oseltamivir phosphate capsules in strengths of 30, 45, and 75 mg. The product is a generic version of Hoffman-La Roche's Tamiflu, indicated to treat acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks and older who have been symptomatic for no longer than 48 hours. It is also indicated for the prophylaxis of influenza A and B in patients 1 year and older.

DOSAGE FORM: Capsule

FOR MORE INFORMATION: alembicpharmaceuticals.com

DOXYLAMINE SUCCINATE AND PYRIDOCINE HYDROCHLORIDE DELAYED-RELEASE TABLETSMARKETED BY: Teva Pharmaceutical Industries Ltd

COMPARE TO: Diclegis

Teva has released doxylamine succinate and pyridoxine hydrochloride delayed-release tablets in strengths of 10 mg and 10 mg, respectively. The drug, a generic version of Duchesnay's Diclegis, is used to treat nausea and vomiting associated with pregnancy in women whose symptoms have not improved with change in diet or other nonmedical treatments. The drug is available in bottles of 100 tablets.

DOSAGE FORM: Tablet

FOR MORE INFORMATION: tevagenerics.com

DORZOLAMIDE AND TIMOLOL MALEATE EYE DROPSMARKETED BY: FDC Ltd

COMPARE TO: Cosopt

FDC Ltd recently received FDA approval for dorzolamide and timolol ophthalmic solution in doses of 22.3 and 6.83 mg/mL. A generic version of Oak Pharmaceuticals' Cosopt, it is indicated to reduce elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma who are unresponsive to β-blockers. The drops work by blocking the β receptors in the eye, reducing the amount of fluid that is produced.

DOSAGE FORM: Eye drop

FOR MORE INFORMATION: fdcindia.com

DANTROLENE CAPSULESMARKETED BY: Lannett

COMPARE TO: Dantrium

Lannett has entered into a 3-year agreement to be the exclusive US distributor of dantrolene capsules. The capsules, available in strengths of 25, 50, and 100 mg, are indicated to treat clinical muscle spasticity resulting from upper motor neuron disorders, such as cerebral palsy, multiple sclerosis, and stroke. Under agreement with Elite Pharmaceuticals, Lannett will provide primarily sales, marketing, and distribution support for the product.

DOSAGE FORM: Capsule

FOR MORE INFORMATION: lannett.com